Factor Therapeutics Ltd (ftt) Logo

Factor Therapeutics Ltd (FTT)

___:___ · Healthcare
0.00
0.00
(0.00)
VOLUME
DIV YIELD
PE RATIO
1 YR RETURN
52 WEEK RANGE

FTT Chart

Snapshot

FTT's Principal Activity is the identification and diligence of potential new business opportunities for the Company.

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume
Volume (4w avg)
Turnover
Open
Day Range -
VWAP
Prev Close
Last Trade

Performance

1 Week
1 Month
2021 YTD
1 Year
vs Sector (1yr) -4.01%
vs ASX 200 (1yr) -9.75%

Size

Market Capitalisation
ASX Rank 2,374 of 2,373
Sector Rank 202 of 204

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies AEB / MEQ / MGZ
EPS -$0.001
DPS $0.00
NTA per share $0.00

Broker Consensus

FTT is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.

Announcements

Date Heading Pages File Size Time

Corporate Overview

Factor Therapeutics (FTT, formerly Tissue Therapies Limited) is a clinical-stage life sciences company. It develops treatments for acute and chronic wound healing applications, including chronic skin ulcers and burns. FTT is commercialising VF-001, a technology for cell based therapies. FTT is also developing treatments for psoriasis, scar prevention and various cancers including those of the breast, colon and prostate.

Incorporation Details

Incorporated Tissue Therapies Limited was incorporated on 6 September 2002 in Queensland

Corporate Details

Head Office Brisbane QLD 4000
Website www.factor-therapeutics.com
Registry Link Market Services
Auditor PKF BRISBANE AUDIT
Date Listed 19 Mar 2004

Upcoming Calendar (Forecasted)

Date Event
23/02/2022 Report (Prelim)
23/02/2022 Report (Annual)
27/07/2022 Report (Interim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Mr Stephen Kelly Chief Financial Officer,Joint Company Secretary Oct 2021
Dr David Lionel Brookes Non-Executive Director,Non-Executive Chairman Apr 2019 Director Bio icon

Dr David Lionel Brookes

Non-Executive Director,Non-Executive Chairman

Dr Brookes has experience in the health and biotechnology industries and is currently a Non-Executive director of Anatara Ltd (ASX:ANR) and TALi Digital Limited (ASX:TD1). He has previously been a director of several other ASX listed biotechnology companies, most recently as the Chairman of genomics solutions company, RHS Ltd, which was acquired by PerkinElmer Inc in June 2018. Until its acquisition in January 2021, Dr Brookes was Non-Executive Chairman of the Better Medical Group, and maintains roles as a clinician and a biotechnology industry consultant. He is Member of Risk Management Committee.

Mr John Michailidis Non-Executive Director Feb 2017 Director Bio icon

Mr John Michailidis

Non-Executive Director

Mr Michailidis is currently the Managing Director for TEVA Australia/NZ and brings over 30 years of commercial pharmaceutical experience to Factor, most recently as Managing Director for TEVA, Australia and New Zealand. His career has ranged from global franchise and regional executive leadership roles with F. Hoffman - La Roche (Roche) to CEO experience with growth-stage biopharmaceutical companies, such as AviPep and Orphan Australia (acquired by Sigma). He is Chair of Risk Management Committee.

Ms Melanie Farris Non-Executive Director,Joint Company Secretary Sep 2016 Director Bio icon

Ms Melanie Farris

Non-Executive Director,Joint Company Secretary

Ms Farris is an experienced governance and corporate operations professional and non-executive director with over 13 years' experience in listed life sciences companies, as well as experience in the planning, management and delivery of strategic corporate activities including IPO and M&A due diligence and integration. Ms Farris previously served as Non-Executive Director and Company Secretary for Invion Limited (ASX: IVX); and Chairperson of Synapse Australia Limited. She is currently Chief Governance and Risk Officer and Group Company Secretary for Telix Pharmaceuticals Limited (ASX:TLX).

Director Transactions

FTT directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
27/09/21 Melanie Farris Issued 204,525 $0.04 $8,181 Director remuneration
27/09/21 David Brookes Issued 1,121,250 $0.04 $44,850 Director remuneration

Director Interests

The current holdings of FTT directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
John Michailidis 27/09/2021 0 862,143 100,000 N/A
Melanie Farris 27/09/2021 204,525 N/A 25,000 N/A
David Brookes 27/09/2021 0 1,280,000 500,000 N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Jan 13, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Calama Holdings Pty Ltd 40,000,000 3.84%
GP Securities Pty Ltd 28,607,989 2.74%
Citicorp Nominees Pty Limited 24,261,921 2.33%
Yelwac Pty Ltd 22,594,216 2.17%
Symington Pty Ltd 19,700,000 1.89%
HSBC Custody Nominees (Australia) Limited 16,314,861 1.56%
Mr Jules Christian Wilson 15,099,502 1.45%
Dr Alok Jhamb 15,000,000 1.44%
Mr Francis Xavier Parnis & Mrs Sally Jane Parnis 14,554,598 1.40%
Mr Michael Andrew Whiting & Mrs Tracey Anne Whiting 12,876,085 1.23%
Nurragi Investments Pty Ltd 12,850,000 1.23%
Mr Kevin John Day 12,500,000 1.20%
Mr Konstandinos Emmanouil 12,000,000 1.15%
Harold Cripps Holdings Pty Ltd 11,623,027 1.11%
Mr Anthony Bratton 10,986,115 1.05%
Jetosea Pty Ltd 10,000,000 0.96%
Aglub Investments Pty Ltd 9,945,731 0.95%
Ms Pharoth San & Mr Kaden San 9,500,000 0.91%
Gattenside Pty Ltd 9,033,037 0.87%
Queensland University Of Technology 8,087,010 0.78%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 201 84 170 986 811 2,252

Substantial Shareholders

No Substantial Shareholders for FTT in our database.

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2020 $0.003 30 June
2019 $0.004 28 June
2018 $0.047 29 June
2017 $0.062 28 June
2016 $0.034 28 June
Page Icon
FTT Historical Price Data (CSV)
Up to 20 years of EOD share price history
Lock Icon
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.